aTyr Pharma to Participate in October Virtual Investor Events
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that the company will
participate in two upcoming virtual investor events in October.
Sanjay S. Shukla, M.D., M.S., President and
Chief Executive Officer, will participate in a virtual question and
answer webinar as part of the ROTH Capital Partners’ CEO Talk
Series on October 12 at 12:00pm ET. Registration for the webinar is
available on the Investor’s section of the Company’s website at
Jill M. Broadfoot, Chief Financial Officer, will
present a corporate overview as part of the Company Presentations
at the BIO Investor Forum Digital international biotech investor
conference which is being held October 13-15. The conference will
take place in a virtual format. aTyr’s company presentation will be
available on-demand for registered attendees of the BIO Investor
Forum Digital to view. For more information, please visit
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Relations, aTyr Pharmaadunston@atyrpharma.com